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to clinically observed differences in PV flow. Methods: A mathematical model
of the atrium with two PVs was developed using an elastance model to de-
scribe pressure-volume relations. Using the unsteady Bernoulli equation in a
system of differential equations, an analytical solution of systolic PV flow in
each vein was achieved. Using the same conditions of initial atrial pressure
(10 mmHg) and relaxation, PV length was varied in one vein (5-15 cm). while
PV length remained constant (10 cm) in the other PV Results: As PV length in-
creased (more blood to be accelerated and greater inertia), peak systolic PV
flow decreased from 105 to 50 cmls in that vein, while peak flow increased in
the other from 55 to 70 cmls, even though its length was constant, reflecting
the reduced LA pressure response to less volume influx from the other pv.
Conclusions: PV inertance (length) is a major determinant of PV flow. As PV
inertia increases, peak systolic flow velocity decreases. PV flow in one vein
influences flow in another. Hence, differences in PV vein length and inertance
may be responsible for the differences in PV flow seen clinically in the same
atrium. and may also mimic or mask differences created by MR jets.
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1 1021-591 Influence of Cardiac Pacing Mode on Left Atrial
Appendage Function: Implication for the Cause
of Systemic Embolism in WI Pacing
ing warfarin had an event (p = 0.0009). Similarly when pts with and with-
out vascular events were compared, no differences in plaque dimensions
were found. In conclusion, mobile aortic plaque is associated with a high
frequency of vascular events during a relatively brief period of follow-up. Al-
though no morphologic aspect of the plaque predicts an event, it appears
that warfarin may provide adequate prophylaxis.
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Converting Enzyme Inhibition Decreases Infarct
Collagen and Limits Hypertrophy of Non-Infarct
Myocardium During Healing After Infarction
Bodh I. Jugdutt. University ofAlberta, Edmonton. Alberta, Canada
Inhibition of tissue angiotensin-converting-enzyme (ACE) activity can poten-
tially block both myocyte and fibroblast growth. The effects of 6 weeks of
ACE inhibition with enalapril (2.5 mg b.Ld.) and captopril (50 mg b.Ld.) on
in vivo changes in LV mass (two-dimensional echocardiography) and post-
mortem myocardial collagen content (hydroxyproline, mglg dry weight) were
measured during healing after anterior infarction (left anterior coronary artery
ligation) in 63 instrumented dogs (34 ACE inhibition: 29 placebo). Compared
to the placebo group. both ACE inhibitors prevented the increase in LV di-
astolic volume (+51 % versus -1.5%, p < 0.001) and LV mass (-3% versus
+ 13%, P < 0.005) over the 6 weeks. However, compared to placebo, ACE
inhibition decreased infarct collagen but not non-infarct collagen.
Hiroyuki Yoshitomi, Kazuaki Tanabe, Yo Murakami, Toshihlko Asanuma.
Hiromi Shimizu, Sachiko Yamada, Kazuya Sano. Toshio Shimada.
Shigefumi Morioka. Shimane Medical University. Izumo, Japan
A higher incidence of systemic embolism has been observed in patients with
WI pacing compared to DDD pacing. However. the cause of systemic em-
bolism in WI pacing remains unclear. Previous studies have demonstrated
that thrombus formation and systemic embolization are related to left atrial
appendage (LAA) dysfunction. To investigate the influence of pacing mode
on LAA function, we performed transesophageal echocardiography in 16 pa-
tients (mean age 65) with permanent DDD pacemakers. The indications for
pacemaker implantation were third degree atria-ventricular block (A-V block,
n = 10) and sick sinus syndrome (SSS, n = 6). All had shown sinus rhythm
at implantation. We measured peak LAA emptying and filling flow velocities
during both DDD and WI pacing at 60 beats/min. The data are summarized
below:
Infarct center
Normal zone
Captopril (23)
31 ± 2*t
5±0
Enalapril (II)
23 ± 5*
5±0
Placebo (29)
45 ± 3
5±0
Plaque Dimensions Vascular
Immobile Component Mobile Component Event
Height Width Area Height Width Area
WAR(n ~ 19) 7±3 29 ± 13 13 ± 6 8±9 3±3 5±8 0
NoWAR(n ~ 10) 6±2 30 ± 15 12 ± 8 7±4 3±2 2±3 6 (60%)
P NS NS NS NS NS NS 00009
Peak LAA flow velocities decreased significantly when a pacemaker was
reprogrammed from DDD to WI pacing mode. especially in patients with
SSS.
Conclusion: LAA function was impaired in WI pacing compared with that
in DDD pacing. These results suggest that impaired LAA function in WI pac-
ing may predispose the chamber to thrombus formation, which may playa
role in the mechanism of the embolization.
W.R. Craig, F.A. Dressler, L.M. Vaughn, D.E. Gamblin, A.J. Labovitz. Saint Louis
University Health Sciences Center
Although the mobile component of plaque is thought to represent thrombus,
the efficacy of anticoagulation has not been proven. In order to assess the
influence of anticoagulation in this population. we studied 29 pts with mobile
plaques found by TEE interrogation of the aortic arch. Each pt had had a
recent systemic embolism: cerebral in 27 (93%) and peripheral in 2 (7%).
After TEE, pt treatment was determined by physician preference. Follow-
up (mean 13 ± 12 mo.s) was obtained via telephone interview and chart
review. Of the 29 pts studied, 19 (66%) received warfarin (WAR) and 10 (34%)
received either aspirin (7) or no therapy(3). These groups were compared in
regards to dimensions of both mobile and immobile plaque components and
vascular events:
Mortality Results of the Trandolapril Cardiac
Evaluation (TRACE) Trial
*p < 0.001 vs. placebo. t p < 0.1. captopril vs. enalapril
Thus. both enalapril and captopril prevented LV dilatation and hypertrophy
during postinfarct healing. but enalapril decreased infarct collagen slightly
more than captopril. Differences in the effects of ACE inhibitors on myocyte
and fibroblast growth may explain some differences in their effects on postin-
farct remodeling, especially with large infarctions.
Lars K"ber, TRACE Study Group. TRACE study office, Copenhagen, Denmark
The aim of the TRAndolapril Cardiac Evaluation (TRACE) trial was to evaluate
whether mortality of patients with left ventricular (LV) dysfunction shortly
after myocardial infarction (Mil is reduced by long term treatment with an
ACE-inhibitor, regardless of the presence of heart failure or ischemia.
7001 consecutive enzyme confirmed Mis in 27 Danish hospitals were
screened for entry into the study 2-6 days following MI. At screening 2-
dimensional echocardiography was recorded on videotape at the center and
evaluated centrally. Wall motion index (WMI) was evaluated, and patients
with WMI :s 1.2 (corresponding to left ventricular ejection fraction :s 0.35)
were eligible for the study. Heart failure and ischemia did not exclude pa-
tients. After receiving a test dose. patients were randomly allocated to re-
ceive oral treatment with Trandolapril or placebo 3-7 days following the MI.
The primary endpoint was all cause mortality (intention to treat). Follow up
was a minimum of 2 years (range 2-4 years).
Results: 2606 (37%) of the screened Mis had WMI :s 1.2. This represented
a high risk group with an overalll-year mortality of 34%. In contrast, patients
with WMI > 1.2 had a one year mortality of only 12%. Of patients eligible for
the study based on LV function, 1749 patients (67%) were included.
876 patients received Trandolapril and 873 patients Placebo. Baseline char-
acteristics did not differ. Trandolapril caused a highly significant reduction in
overall mortality. Overall risk reduction was 22%, p = 0.0007. At study clo-
sure mortality of Trandolapril treated patients was 35% and that of placebo
treated patients 42%.
Conclusion: Long term treatment with Trandolapril of patients with LV dys-
function shortly after MI, significantly reduced mortality. The study adds to
the results of the SAVE trial by including a large proportion of eligible patients
and not excluding patients with heart failure or ischemia.
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p value
<0.01
<0.05
<0.01
58 ± 18 40 ± 19
41 ±13 24± 7
52 ± 18 34 ± 18
Peak LAA flow velocity (cm/s)
DDD WI
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A-V block (n ~ 101
SSS (n = 6)
Total (n = 16)
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The dimensions of both mobile and immobile components of plaque were
similar in the groups. Vascular events occurred in 6 (60%) of the No WAR
group (4 strokes and 2 myocardial infarctions) while none of the pts receiv-
